JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

Strona główna・Stock List・Ascendis Pharma A/S

Ascendis Pharma A/S

Closed

SectorHealthcare

229.42 4.99

Buy Sell

Overview

Share price change

24h

Current

Min

218.51

Max

230.01

Key metrics
By Trading Economics
Income	28M -33M
Sales	32M 245M
Profit margin	-13.56
Employees	1,189
EBITDA	68M 15M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+33.56% upside

Dividends
By Dow Jones
Next Earnings	7 maj 2026

Market Stats
By TradingEconomics
Market Cap	14B
Previous open	224.43
Previous close	229.42

News Sentiment

By Acuity

50%

186 / 347 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

157.66 / 167.29 Support & Resistance

Ascendis Pharma A/S Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

30 kwi 2026, 23:08 UTC

Earnings

Australia's ANZ Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

30 kwi 2026, 23:07 UTC

Earnings

Australia's Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

30 kwi 2026, 22:20 UTC

Earnings

Australia's ANZ Raises 1st Half Profit 9%, Warns of Coming Iran Impacts

30 kwi 2026, 23:48 UTC

Market Talk

Nikkei May Rise After Gains on Wall Street -- Market Talk

30 kwi 2026, 23:47 UTC

Market Talk

Global Equities Roundup: Market Talk

30 kwi 2026, 23:47 UTC

Market Talk

Coles's Earnings Views Likely to Edge Down Despite Positives -- Market Talk

30 kwi 2026, 23:27 UTC

Market Talk

Liontown Lithium Recovery Expected to Improve -- Market Talk

30 kwi 2026, 23:22 UTC

Earnings

Apple's Incoming CEO John Ternus Makes Appearance as Company Bests Expectations -- Update

30 kwi 2026, 23:20 UTC

Market Talk

Wildcat Resources Stands Out Among Lithium Developers -- Market Talk

30 kwi 2026, 22:52 UTC

Earnings

Australia's ANZ Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

30 kwi 2026, 22:33 UTC

Earnings

Zhejiang Expressway: Impairment Loss Weighed on Net >0576.HK

30 kwi 2026, 22:32 UTC

Earnings

Zhejiang Expressway 1Q Net CNY1.31B Vs. Net CNY1.48B >0576.HK

30 kwi 2026, 22:32 UTC

Earnings

Zhejiang Expressway 1Q Rev CNY5.32B Vs. CNY4.36B >0576.HK

30 kwi 2026, 22:24 UTC

Acquisitions, Mergers, Takeovers

Mineral Resources: Also Reflects Time Needed to Implement Corporate Restructure For JV

30 kwi 2026, 22:23 UTC

Acquisitions, Mergers, Takeovers

Mineral Resources: Revised Timetable Reflects Time Needed to Get Regulatory Approvals

30 kwi 2026, 22:23 UTC

Acquisitions, Mergers, Takeovers

Mineral Resources: Now Expects Deal to Complete in 1H FY2027

30 kwi 2026, 22:23 UTC

Acquisitions, Mergers, Takeovers

Mineral Resources: Executes Key Formal Agreements With Posco on Stake Sale

30 kwi 2026, 22:11 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

30 kwi 2026, 22:11 UTC

Market Talk

Global Equities Roundup: Market Talk

30 kwi 2026, 22:11 UTC

Market Talk

Apple Says Demand for Lower-Cost Laptop is Off the Charts -- Market Talk

30 kwi 2026, 22:05 UTC

Earnings

Australia's ANZ Raises 1H Profit 9%, Warns of Coming Iran Impacts

30 kwi 2026, 21:57 UTC

Earnings

ANZ CEO: Increase in Collective Provisions Reflects Risk>ANZ.AU

30 kwi 2026, 21:56 UTC

Earnings

ANZ CEO: Minimal Impact on ANZ's Credit, Capital, Liquidity>ANZ.AU

30 kwi 2026, 21:56 UTC

Earnings

ANZ CEO: No Material Increase in New Cases of Household Hardship>ANZ.AU

30 kwi 2026, 21:55 UTC

Earnings

ANZ CEO: Households Entered Crisis With Generally Strong Balance Sheets>ANZ.AU

30 kwi 2026, 21:54 UTC

Earnings

ANZ CEO: No Material Change in Overall Corporate Borrowing Behavior >ANZ.AU

30 kwi 2026, 21:54 UTC

Earnings

ANZ CEO: Corporate Customers Have Been Building Capital, Liquidity Against Shocks>ANZ.AU

30 kwi 2026, 21:53 UTC

Earnings

ANZ CEO: Much of Iran Conflict's Potential Impact Remains Ahead>ANZ.AU

30 kwi 2026, 21:49 UTC

Earnings

ANZ Group 1H Total Operating Income A$11.20B Vs. A$10.995B>ANZ.AU

30 kwi 2026, 21:49 UTC

Earnings

ANZ Group 1H Customer Deposits A$770.7B Vs. A$756.6B>ANZ.AU

Peer Comparison

Price change

Ascendis Pharma A/S Forecast

Price Target

By TipRanks

33.56% upside

12 Months Forecast

Average 296.62 USD 33.56%

High 342 USD

Low 255 USD

Based on 13 Wall Street analysts offering 12 month price targets forAscendis Pharma A/S - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

13 ratings

Buy

Hold

Sell

Based on 13 analysts giving stock ratings to Ascendis Pharma A/S - Dist in the past 3 months.

Technical Score

By Trading Central

157.66 / 167.29Support & Resistance

Recent bearish events outweigh bullish events.

Bullish events outweigh bearish events.

All events are bullish.

Sentiment

By Acuity

186 / 347 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

Other stocks from the sector

JNJ

Johnson and Johnson

229.87

↑ +1.14%

UNH

UnitedHealth Group Inc

370.84

↑ +0.14%

TMO

Thermo Fisher Scientific Inc

478.44

↑ +2.91%

ISRG

Intuitive Surgical Inc

457.44

↑ +1.12%

ABT

Abbott Laboratories

90.76

↓-0.82%

Ascendis Pharma A/S

Overview

Share price change

Key metrics

Recommendations

Dividends

Market Stats

News Sentiment

Technical Score

Ascendis Pharma A/S Chart

Related News

Peer Comparison

Ascendis Pharma A/S Forecast

Price Target

Rating Consensus

Technical Score

Sentiment

Financials

Other stocks from the sector